Application of ASB3 in preparation of drugs for treatment of non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the field of gene function, can solve the problem of less function of ASB3 gene, and achieve the effect of reducing fat accumulation, less side effects, and inhibiting content
CN110478485AActive Publication Date: 2019-11-22AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
4 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Publication Date
2019-11-22

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of gene function, and in particular, relates to an application of an ASB3 gene in preparation of drugs for treatment of non-alcoholic fatty liver disease. The advantages comprise that by constructing an ASB3 gene fully knockout mouse model, the content of E3 ubiquitin ligase ASB3 in vivo can be inhibited, and the beta-oxidation and oxygen consumption of long-chain fatty acids can be enhanced, so as to reduce lipid accumulation in hepatocytes. The invention discloses new functions of the ASB3 gene and provides new targets and ideas for treatment of non-alcoholic fatty liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention relates to the field of gene function, specifically, the discovery of new functions of the ASB3 gene, that is, the application of the ASB3 gene in the preparation of drugs for treating metabolic diseases. Background technique

[0002] Nonalcoholic fatty liver disease (NAFLD) is a liver disease, which is related to visceral lipid accumulation and metabolic disorders, and it plays an increasingly important role in diseases that ultimately lead to liver fibrosis and liver tumors. . There are no accurate data on the incidence of NAFLD, but it is estimated that its global incidence is in the range of 28.01 / 1000 person-years to 52.34 / 1000 person-years; and the prevalence is about 25% (Younossi ZM, Koenig AB, Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.). Among them, the prevalence rate is 24.13% in North America, 30.45% in Sou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More